| Name | Title | Contact Details |
|---|---|---|
Sherry Wiffen |
Director, Human Resources / HRBP R&D, Operations & Manufacturing | Profile |
Kelly Cicchelli |
Director Total Rewards | Profile |
Sherry Wiffen |
Director, Human Resources | Profile |
Melissa Simonsen |
Director, Talent Acquisition | Profile |
Kristin Martin |
Chief Human Resources Officer | Profile |
Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics.
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent`s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying PLX9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.
We are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to our lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). We bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers. We are bold in our mission and purpose and aim for nothing less than a transformative impact on people`s lives.
Vanessa is a Rockland, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We aim to design a new world of proteins to address 21st century challenges in medicine, energy, and technology.